Trial Profile

A phase III registration trial of OK-101

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 13 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Urcosimod (Primary)
Indications Dry eyes
Focus Adverse reactions; Registrational
Sponsors OKYO Pharma

Most Recent Events

08 Jan 2024 According to OKYO Pharma media release, the company will work with scientific advisers and seek additional FDA guidance on next steps to designing a Phase 3 trial.
21 Feb 2023 According to Okyo media release, the CEO of company will give an oral presentation entitled "A lapidated Protease-Resistant Chemerin Peptide Offers a Novel Therapeutic for Dry Eyes" on February 22, 2023 at the 2nd annual GPCRs-Targeted Drug Discovery Summit at the Hyatt Regency in Boston, MA.
01 Sep 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com